Temodar disposal

An amendment to the Plan so that each Right entitles the holder to purchase one one-thousandth of a share of Series A Preferred Stock at a price of 5 per one one-thousandth of a share, subject to adjustment. On August 7, 2006, the Board of Directors approved an amendment to the Plan to accelerate the expiration date to August 18, 2006, effectively terminating the Plan as of that date. Stock plans 2004 Equity Incentive Award Plan. In December 2004, stockholders approved the 2004 Equity Incentive Award Plan the "2004 Plan" ; as a replacement for both the company's 1995 Stock Option Plan the "1995 Plan" ; and the 1995 Non-Employee Directors Stock Option Plan the "Directors Plan" ; . The adoption of the 2004 Plan included an increase of 600, 000 in the number of shares available for issuance over the remaining shares available for issuance under the 1995 Plan and Directors Plan. In December 2005, the stockholders approved an increase of 1, 000, 000 shares available for issuance under the 2004 Plan. The 2004 Plan provides for the issuance of various types of equity awards, such as incentive stock options, nonstatutory stock options stock, restricted stock, stock appreciation rights and performance shares. The exercise price of all stock options granted under the 2004 Plan may not be less that the fair market value of the company's common stock on the date of grant and no stock option will be exercisable more than ten years after the date it is granted. Stock options for employees and consultants typically vest over four years. Non-employee Directors receive annual, automatic, non-discretionary grants of nonqualified stock options. Each new non-employee Director receives an option to purchase 10, 000 shares as of the date he or she first becomes a Director. This option grant vests in equal annual installments over five years. In addition, on the date of each annual meeting, each individual reelected as a non-employee Director will receive an automatic option grant to purchase an additional 7, 500 shares of common stock, provided such individual has served as a Director for at least six months prior to the date of grant. This option grant vests in equal monthly installments over twelve months following the date of grant. 1995 Stock Option Plan. The company's 1995 Plan was adopted by the Board of Directors in August 1995. Options issued under the 1995 Plan can, at the discretion of the plan administrator, be either incentive stock options or nonqualified stock options. In December 2003, the stockholders approved amendments to the 1995 Plan i ; such that the exercise price of all stock options must be at least equal to the fair value of Pharmacyclics' common stock on the date of grant and ii ; that increased the total number of authorized shares under the plan to 5, 345, 724 shares of common stock. Generally, shares subject to options under the 1995 Plan vest over a four or five year period and are exercisable for a period of ten years. In December 2004, the remaining shares available for future grant under the 1995 Plan were transferred to the 2004 Plan. Additionally, if options granted under the 1995 Plan expire or otherwise terminate without being exercised, the shares of common stock reserved for such options again become available for future grant under the 2004 Plan. 1995 Non-Employee Directors Stock Option Plan. The company's Directors Plan was adopted by the Board of Directors on August 2, 1995 and provides for issuance of common stock to non-employee Directors pursuant to a predetermined formula. The exercise price of options granted under the Directors Plan must be at least equal to the fair value of Pharmacyclics' common stock on the date of grant. Each individual first elected or appointed as a non-employee Board member will automatically be granted, on the date of such election or appointment, a non-statutory option to purchase 10, 000 shares of common stock vesting over five years. In addition, on the date of each annual stockholders' meeting each individual who is to continue to serve as a non-employee Board member after that annual meeting and has been a member of the Board for at least six months will automatically be granted a non-statutory option to purchase 5, 000 shares of common stock. A total of 271, 667 shares of common stock have been reserved for issuance under the Directors Plan. In December 2004, the remaining shares available for future grant under the Directors Plan were transferred to the 2004 Plan. Additionally, if options granted under the Directors Plan expire or otherwise terminate without being exercised, the shares of common stock reserved for such options again become available for future grant under the 2004 Plan. The following table summarizes the company's stock option activity in thousands, except per share amounts.

Systems of display are starting points from which the group allows itself all manner of consumer-age liberties. BankMalbekRau installations encompass not only a sense of the pre-modern fascination with the esoteric and exotic, but also a gather in domestic objects and consumer goods, including but not limited to jewelry, ornaments, furniture, various household wares, consumer electronics, sports gear, and architectural elements. The Paintbox Extensions installation in Copenhagen in 2004, shown on the cover and following Prescription medicine datasheets bleedingedge » drugs » tikosyn abilify aciphex actonel actos acutect agenerase aggrastat alamast alimta alinia aloxi alrex amerge angiomax antagon apidra arava argatroban arixtra aromasin atacand avandia avelox avodart axert azopt benicar bextra boniva cancidas celebrex celexa cetrotide cialis clarinex colazal comtan crestor cubicin curosurf definity detrol elestat elidel ellence emend emtriva erbitux ertaczo - evoxac exelon extraneal factive faslodex ferrlecit foradil frova fuzeon geodon gleevec hectorol hepsera infasurf innohep inspra integrilin iressa kaletra keppra ketek - lantus levitra levulan lotemax lumigan maxalt micardis mobic mylotarg namenda natrecor neotect kit novolog orfadin ortho evra orth tri-cyclen - panretin pletal precedex priftin protonix provigil radiogardase rapamune raptiva refludan relenza renagel rescula - reyataz sensipar singulair solage somavert sonata spectracef spiriva - starlix strattera sucraid sustiva synercid tamiflu targretin tasmar temodar tequin thalomid thyrogen tikosyn travatan trileptal trisenox uroxatral valstar velcade viagra vioxx visudyne vitravene welchol xeloda xenical xopenex yasmin zaditor zavesca zelnorm zemplar zetia ziagen zometa zonegran zyvox tikosyn brand name : pfizer inc * approval by fda does not mean that the drug is available for consumers at this time and tenofovir.

Within six weeks after the histologic diagnosis of glioblastoma, we randomly assigned eligible patients to receive standard focal radiotherapy alone the control group ; or standard radiotherapy plus concomitant daily temozolomide, followed by adjuvant temozolomide. Randomization was performed at the EORTC Data Center, and patients were stratified according to WHO performance status, whether or not they had previously undergone debulking surgery, and the treatment center.20 The assigned treatment had to begin within one week after randomization. Radiotherapy consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week Monday through Friday ; over a period of six weeks, for a total dose of 60 Gy. Radiotherapy was delivered to the gross tumor volume with a 2-to-3-cm margin for the clinical target volume. Radiotherapy was planned with dedicated computed tomography CT ; and three-dimensional planning systems; conformal radiotherapy was delivered with linear accelerators with nominal energy of 6 MV more, and quality assurance was performed by means of individual case reviews.21 Concomitant chemotherapy consisted of temozolomide marketed as Temodal in Europe and Temodar in the United States and Canada; Schering-Plough ; at a dose of 75 mg per square meter per and terfenadine.